<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462020000200116</article-id>
<article-id pub-id-type="doi">10.35366/94638</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Recomendaciones de los Expertos para la Concientización del Asma en México]]></article-title>
<article-title xml:lang="en"><![CDATA[Recommendations from Experts for Asthma Awareness in Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuevas-Schacht]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Vera]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Estrada]]></surname>
<given-names><![CDATA[Erika del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Magdaleno-Maldonado]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maldonado-Hernández]]></surname>
<given-names><![CDATA[Juan Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moncayo-Coello]]></surname>
<given-names><![CDATA[Carol Vivian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojo-Gutiérrez]]></surname>
<given-names><![CDATA[María Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa-Vázquez]]></surname>
<given-names><![CDATA[Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pech-Alonso]]></surname>
<given-names><![CDATA[Baltazar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llópiz-Avilés]]></surname>
<given-names><![CDATA[Marlene Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Boy-Ojeda]]></surname>
<given-names><![CDATA[Antonieta Esperanza]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lezama-Armenta]]></surname>
<given-names><![CDATA[Andrés Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Lomas  ]]></institution>
<addr-line><![CDATA[Huixquilucan Estado de Mexico]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,ISSSTE Hospital Regional Lic. Adolfo López Mateos Hospital Médica Sur]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,SEDENA Hospital Central Militar ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Secretaría de la Defensa Nacional  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital Juárez de México  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Consejo Mexicano de Inmunología Clínica y Alergia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,IMSS Hospital General Gaudencio González Garza Unidad Médica de Alta Especialidad La Raza]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Hospital Ángeles Acoxpa Centro Médico Naval ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Instituto Médico de Capacitación  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>79</volume>
<numero>2</numero>
<fpage>116</fpage>
<lpage>120</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462020000200116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462020000200116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462020000200116&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El informe de estrategias de GINA (del inglés Global Initiative for Asthma) 2019 presenta los cambios más relevantes en el manejo del asma en los últimos 30 años.  Objetivo:  El propósito de este artículo es la difusión de los cambios en GINA 2019 con respecto al tratamiento del asma leve, así como expresar la postura del grupo de Expertos para la Concientización del Asma en México (ECAM), y sus recomendaciones a toda la comunidad médica tras el estudio minucioso de los cambios y la evidencia científica que los sustenta.  Metodología:  Se reunió a un grupo de médicos especialistas, líderes de opinión y expertos en asma en México con la finalidad de revisar, analizar y discutir los estudios y la evidencia que sustentan los cambios en GINA 2019.  Resultados:  Se definieron posturas y estrategias para abordar los diferentes retos que podrían presentarse debido a los cambios.  Conclusiones:  La recomendación es que todo paciente asmático debe tener tratamiento antiinflamatorio. Una estrategia en pacientes con síntomas intermitentes es utilizar una dosis baja de corticosteroide inhalado/formoterol por razón necesaria (PRN) como medicamento preferido de rescate; y en pacientes con síntomas persistentes, utilizar dosis bajas diarias de corticosteroides inhalados/formoterol como tratamiento de control y de rescate PRN. Los resultados de los estudios y su impacto en la práctica clínica son prometedores.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The 2019 GINA strategy report presents the most relevant changes in asthma management in the last 30 years.  Objective:  The purpose of this article is to disseminate the changes in GINA 2019 regarding the treatment of mild asthma, and to express the position and recommendations from the members of the experts for awareness of asthma in Mexico.  Methodology:  A group of opinion leaders and asthma experts in Mexico was brought together to discuss the studies and evidence that support the changes in GINA 2019.  Results:  Positions and strategies were defined to address the different challenges posed by these changes.  Conclusions:  The recommendation is that every asthma patient should receive anti-inflammatory treatment. One strategy in patients with intermittent symptoms is to use a low-dose inhaled corticosteroid/formoterol as a preferred reliever, and daily low dose ICS/formoterol both as control and rescue (as needed) treatment for patients with persistent symptoms. The results of the studies and their impact on clinical practice are promising.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Asma]]></kwd>
<kwd lng="es"><![CDATA[tratamiento antiinflamatorio]]></kwd>
<kwd lng="es"><![CDATA[budesónida]]></kwd>
<kwd lng="es"><![CDATA[formoterol]]></kwd>
<kwd lng="es"><![CDATA[corticosteroides inhalados]]></kwd>
<kwd lng="en"><![CDATA[Asthma]]></kwd>
<kwd lng="en"><![CDATA[anti-inflammatory treatment]]></kwd>
<kwd lng="en"><![CDATA[budesonide]]></kwd>
<kwd lng="en"><![CDATA[formoterol]]></kwd>
<kwd lng="en"><![CDATA[inhaled corticosteroids]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Global Initiative for Asthma</collab>
<source><![CDATA[Pocket Guide for Asthma Management and Prevention (for adults and children older than 5 years)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Byrne]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bateman]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhaled combined budesonide-formoterol as needed in mild asthma. (SYGMA 1)]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1865-76</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bateman]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Reddel]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Byrne]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. (SYGMA 2)]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1877-87</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beasley]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Holliday]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reddel]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlled trial of budesonide-formoterol as needed for mild asthma. (Novel Start)]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2020-30</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dusser]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Montani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chanez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2007</year>
<volume>62</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>591-604</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddel]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Ampon]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Sawyer]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suissa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Boivin]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1994</year>
<volume>149</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>604-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hancox]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Flannery]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Herbison]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[McLachlan]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2000</year>
<volume>94</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>767-71</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
